BXTA heeft zich ten doel gesteld de wereld te informeren over de voordelen van transperineale biopsie onder lokale verdoving, afgekort als LATP (Local Anaesthetic Transperineal Prostate).

As the sole distributor, outside North America, for the PrecisionPoint™ single use device, that enables LATP, and alongside international partners that including organisations such as the British Association of Urological Surgeons, The Royal Society of Medicine, Prostate Cancer UK, The British Association of Urological Nurses and many others, we are committed to eradicating the current ‘de facto’ standard method for prostate cancer diagnosis: the transrectal ultrasound (TRUS) guided or transrectal biopsy.

Yet, TRUS biopsy has a high risk of infection, including patients given prophylaxis medication. In a recent study, 7 of 564 patients who received TRUS were admitted to the hospital for infection within the first 7 days, compared to 1 of 562 patients for LATP. At 4 months, 13 patients who received TRUS had required hospital admission, compared to 6 patients who had received LATP¹. The alternative transperineal or template (TP) biopsy has, in the past, typically only been available to men at greater risk of infection from certain medical conditions, and had to be done under general anaesthetic because of the need for multiple biopsy punctures

The PrecisionPoint™ Transperineal Access System is now revolutionising the methodology for obtaining prostate biopsies. Not only does it take full advantage of the transperineal path, decreasing risk of infections, it allows for more thorough sampling of all regions of the prostate including those difficult to access with the transrectal approach². 

PrecisionPoint™ provides a free-hand experience for HCP to operate in local anaesthetic settings, potentially aiding hospitals with limited resources.

• Handig uit de vrije hand, gemakkelijk te leren
• Decreases risk of sepsis over the transrectal approach, removing the necessity for routine antibiotic use thereby decreasing the risks of the spread of antibiotic-resistant micro-organisms³
• Maakt het mogelijk om systematisch sjabloongebaseerde monsters te nemen, zonder gebruik van een sjabloon, stepper of stabilisator⁴
• Behandeling onder plaatselijke verdoving en dus poliklinisch mogelijk

By passing the biopsy needle through the perineum instead of the rectum, the risks associated with the transrectal approach are reduced. The practitioner is not restricted to biopsy locations dictated by a grid configuration, since the technique is freehand. The practitioner can freely manoeuvre the ultrasound probe to align the access needle to target the desired locations with certainty for targeted and systematic biopsies.

PrecisionPoint™ represents a novel approach for urologist to obtain samples in difficult areas of the prostate⁵ compared to TRUS procedures, through it’s ability to systematically allow access to the whole of the gland.

BXTA werkt samen met vooraanstaande urologen, gespecialiseerd klinisch verpleegkundigen en experts op het gebied van prostaatkankerdiagnose om de TRUS-biopsie te vervangen door LATP als de nieuwe standaard in de zorg.

We hebben regionale centra van klinische excellentie opgericht in Europa, Australië en Nieuw-Zeeland, als onderdeel van een internationaal trainingsprogramma om het aantal consultanten, assistent-geneeskundigen in opleiding en gespecialiseerd klinisch verpleegkundigen te trainen in deze nieuwe, geavanceerde prostaatbiopsietechniek.

Referenties

1. Local anaesthetic transperineal biopsy versus transrectal prostate biopsy in prostate cancer detection (TRANSLATE): a multicentre, randomised, controlled trial. Richard J Bryant, Ioana R Marian, Roxanne Williams, J Francisco Lopez, Claudia Mercader, Mutie Raslan, et al. The Lancet Oncology, Volume 26, Issue 5, 583 – 59, 2025.
2. Is There an Impact of Transperineal Versus Transrectal Magnetic Resonance Imaging-targeted Biopsy in Clinically Significant Prostate Cancer Detection Rate? A Systematic Review and Meta-analysis. Uleri A, Baboudjian M, Tedde A, Gallioli A, Long-Depaquit T, Palou J, et al. Eur Urol Oncol. Dec;6(6):621-628, 2023.
3. EXIT from TRansrectal prostate biopsies (TREXIT): sepsis rates of transrectal biopsy with rectal swab culture guided antimicrobials versus freehand transperineal biopsy. Newman, T.H., Stroman, L., Hadjipavlou, M. Haque, A., Rusere, J., Chan, K., et al. Prostate Cancer Prostatic Dis 25, 283–287, 2022
4. Transperineal Magnetic Resonance Imaging-Fusion Targeted Prostate Biopsy Utilizing the PrecisionPoint Transperineal Access System vs a Grid Template: An Assessment of Outcomes. Buller D, Lin F, Wagner J, Antony M, Staff I, McLaughlin T, Tortora J, et al. Urology. 2025
5. Anterior prostate cancer: is it more difficult to diagnose? Bott SR, Young MP, Kellett MJ, Parkinson MC. BJU Int. Jun;89(9):886-9. 2002